Archive ready
味の素株式会社、アステラス製薬とライセンス契約を締結
https://www.ajinomoto.co.jp/company/jp/ir/news/news-20251031/main/0/link/20251031_J.pdfMay 27, 2026 at 03:45 AM JST•The archive page, viewer, and downloads use this saved version.
May 27, 2026 at 03:45 AM JST·www.ajinomoto.co.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved PDF
味の素株式会社、アステラス製薬とライセンス契約を締結
StartedMay 27, 2026 at 03:45 AM JST
File size0.80 MB
SHA-25683b19ddca8dc7a0a0ff59ce2a6940fa246c87c9022c6bf11f78a8a78bde9e079
About this pageAI generated
This document reports that Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma for the development of antibody-drug conjugates (ADCs). Under this agreement, Ajinomoto will provide its proprietary technology, AJICAP®, to enhance the quality and efficiency of ADC manufacturing. ADCs are expected to see increased demand in cancer treatment due to their reduced side effects, with the market projected to grow significantly from 2023 to 2029. Through this collaboration, Ajinomoto aims to support Astellas in developing innovative therapies, providing new treatment options for patients.